Candel Therapeutics, Inc. CADL Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Candel Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s cash ratio?
- Candel Therapeutics, Inc. (CADL) reported cash ratio of 27.6× in Q1 2026.
- How has Candel Therapeutics, Inc.'s cash ratio changed year-over-year?
- Candel Therapeutics, Inc.'s cash ratio increased by 501.7% year-over-year, from 4.6× to 27.6×.
- What is the long-term trend for Candel Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s cash ratio has grown at a 12.3% compound annual growth rate (CAGR), from 7.4× to 13.3×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.